相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2021 clinical trials update: Innovations in hemophilia therapy
Stacy E. Croteau et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency
Dino Mehic et al.
BLOOD ADVANCES (2021)
Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry
Tobias Koller et al.
SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE (2021)
Hemophilia therapy: the future has begun
Pier Mannuccio Mannucci
HAEMATOLOGICA (2020)
Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity
Stephen MacDonald et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)
Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction
Tami Livnat et al.
BLOOD CELLS MOLECULES AND DISEASES (2020)
Emicizumab treatment and monitoring in a paediatric cohort: real-world data
Assaf A. Barg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas
Sunita Patel-Hett et al.
HAEMOPHILIA (2019)
TFPI blockade: removing coagulation's brakes
Robert F. Sidonio et al.
BLOOD (2019)
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data
Hermann Eichler et al.
HAEMOPHILIA (2019)
Treatment of rare factor deficiencies other than hemophilia
Marzia Menegatti et al.
BLOOD (2019)
A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers
M. Cardinal et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study
Assaf Arie Barg et al.
PEDIATRIC BLOOD & CANCER (2018)
Thromboelastography and thrombin generation assay in inherited afibrinogenemia
Guy Aaron Young et al.
HAEMOPHILIA (2018)
Rare bleeding disorders-old diseases in the era of novel options for therapy
Tami Livnat et al.
BLOOD CELLS MOLECULES AND DISEASES (2017)
Tissue Factor Pathway Inhibitor Multiple Anticoagulant Activities for a Single Protein
Alan E. Mast
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
P. Chowdary et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Combined Deficiency of Coagulation Factors V and VIII: An Update
Chunlei Zheng et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2013)
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
Connie Duckers et al.
BLOOD (2008)
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature
A. Girolami et al.
HAEMOPHILIA (2008)
Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency
O Salomon et al.
BLOOD (2003)
Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis
A Dahm et al.
BLOOD (2003)
分享论文
